T
52.97
0.02 (0.04%)
| Previous Close | 52.95 |
| Open | 52.95 |
| Volume | 3,578,451 |
| Avg. Volume (3M) | 5,753,234 |
| Market Cap | 6,113,447,424 |
| Price / Sales | 302.64 |
| Price / Book | 6.08 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -1.08 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 30.89 |
| Operating Cash Flow (TTM) | -71.66 M |
| Levered Free Cash Flow (TTM) | -44.95 M |
| Return on Assets (TTM) | -22.15% |
| Return on Equity (TTM) | -32.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Terns Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.33 |
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 100.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capitolis Liquid Global Markets Llc | 31 Dec 2025 | 3,045,200 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |